NCT06326697已完成1 期
A Randomized, Single Oral Dose, Open Label, Two Sequence, Two Treatment, Four Periods, Full Replicate Crossover Study to Determine the Bioequivalence of Azacitidine 300 mg Film- Coated Tablets Versus Onureg® 300 mg Film-Coated Tablets for Adult Patients With Acute Myeloid Leukaemia (AML) Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
A Randomized, Single Oral Dose, Open Label, Two Treatment, Crossover study to investigate the bioequivalence of the Test Product Azacitidine 300 mg Film coated tablets relative to Reference Product Onureg® 300 mg Film Coated Tablets in adult patients with AML under fasting conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients age ≥ 18 years of age at the time of signing the informed consent document.
- •Patients with documented diagnosis of AML according to the 2022 updates of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukaemia.
- •Patients with acute myeloid leukemia who achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy. The definitions of response criteria for CR or CRi are primarily those defined by the 2022 report from the European Leukemia Net (ELN) on AML as below: CR defined as bone marrow blasts <5%; absence of circulating blasts; absence of extramedullary disease; ANC ≥ 1.0 × 10^9/L (1,000/µL); platelet count ≥ 100 × 10^9/L(100 000/µL).
- •CRi defined as all CR criteria, except for residual neutropenia < 1.0 × 10^9/L (1,000/µL) or thrombocytopenia < 100 × 10^9/L (100 000/µL).
- •Patients who don't have a known or suspected hypersensitivity to Azacitidine or any other ingredient used in the manufacturing of Azacitidine.
- •Patients who are physically able for appropriate pharmacokinetics sampling according to principal investigator evaluation.
- •Patients who have a haematological profile appropriate for receiving Azacitidine 300 mg dose for 4 consecutive days as per the principal investigator assessment.
- •Patients who understand and voluntarily sign a written informed consent document prior to any study related assessments/procedures are conducted.
- •Patient is capable of consent.
- •Females of childbearing potential may participate, providing the subject meets the following conditions: Negative serum pregnancy test at screening (sensitivity of at least 25 mIU/mL), and willing to use effective contraception during and up to 6 months after study.
- •Male patients must be willing to use effective contraception during and up to 3 months after the study.
排除标准
- •Patients with history of drug or alcohol abuse.
- •Female patients who are pregnant or nursing (lactating).
- •Patients with medical condition, laboratory abnormality, or psychiatric illness that, in the opinion of the investigator, might interfere with subject safety, compliance or evaluation of the condition of the study.
- •Patients with positive blood screen for HIV, Hepatitis B (HbsAG) or Hepatitis C (HCV) virus.
- •Patients with experience in any investigational drug in a clinical study within 6 months prior to study Day
- •Patients has a difficulty fasting or consuming standard meals.
- •Patients has history of difficulties in swallowing or any gastrointestinal disease which could affect the drug absorption.
- •Patients does not agree to not be engaged in strenuous exercise at least one day prior to study drug administration until donating the last sample of the study.
- •Patients does not agree to not consuming any beverages or food containing grapefruit for at least two weeks prior to first study drug administration until donating the last sample of the study.
- •Patients does not agree to not consuming any beverages or food containing methyl-xanthines e.g., caffeine (coffee, tea, cola, energy drinks, chocolate etc.) at least 48 hours prior to first study drug administration until donating the last sample of the study.
- •Patients does not agree to not consuming any alcohol containing beverages and food at least 48 hours prior to first study drug administration until donating the last sample of the study
研究组 & 干预措施
Test Product: Azacitidine 300 mg Film coated tablets
Experimental
Single oral dose of Azacitidine 300 mg Film coated tablets
干预措施: Azacitidine (Drug)
Reference Product: Onureg® 300 mg Film Coated Tablets
Active Comparator
Single oral dose of Onureg® 300 mg Film Coated Tablets
干预措施: Onureg (Drug)
结局指标
主要结局
Cmax
时间窗: 5 hours
Maximum measured plasma concentration over the time span specified
AUC0-t
时间窗: 5 hours
The area under the plasma concentration versus time curve, from time (0) to the last measurable concentration (t), as calculated by the linear trapezoidal method.
次要结局
- Change in clinical safety labs(Day 4)
- AUC0-∞(5 hours)
- Kel(5 hours)
- T1/2el(5 hours)
- Adverse Events (AEs)(Day 4)
- Tmax(5 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
An Open-label, Single-dose, Two-treatment, Randomized, Cross-over Study to Investigate the Effects of the SLCO2B1 c.1457C>T Polymorphism and Apple Juice on the Pharmacokinetics and Pharmacodynamics of Acebutolol in Healthy Korean and Japanese VolunteersHealthyNCT01514019In-Jin Jang, MD, PhD16
已完成
1 期
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.Type 2 Diabetes MellitusNCT06483243Chong Kun Dang Pharmaceutical45
已完成
1 期
A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337DyslipidemiaNCT02651753Chong Kun Dang Pharmaceutical48
撤回
1 期
COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.HealthyNCT02395237Pharmaceutical Research Unit, Jordan
已完成
1 期
A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy ParticipantsHIV InfectionsNCT04263142ViiV Healthcare39